歌礼制药-B股价涨超7% 美国临床研究完成首批给药

iDoNews
21 May

5月21日,歌礼制药-B(01672)早盘涨幅扩大至7.14%,现报6.75港元。公司宣布,ASC47-103研究在美国完成首批受试者给药。该研究评估ASC47联合司美格鲁肽在肥胖受试者中的安全性及初步疗效,采用随机、双盲、安慰剂对照方式。此举标志着公司在肥胖治疗领域取得重要进展,市场反应积极。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10